Logo
x

Search category

Subscribe Now

Arcutis

Arcutis Reports Interim Results from the P-III (INTEGUMENT-OLE) Trial of Roflumilast for Mild to Moderate Atopic Dermatitis

Arcutis Reports Interim Results from the P-III (INTEGUMENT-OLE) Trial of Roflumilast for Mild to Moderate Atopic Dermatitis

  • September 9, 2023
Arcutis Entered into a Collaboration and License Agreement with Huadong for Roflumilast in Greater China and Southeast Asia

Arcutis Entered into a Collaboration and License Agreement with Huadong for Roflumilast in Greater China and Southeast Asia

  • August 11, 2023
Arcutis Reports the US FDA Acceptance of NDA for Roflumilast to Treat Seborrheic Dermatitis in Individuals Aged ≥9 Years

Arcutis Reports the US FDA Acceptance of NDA for Roflumilast to Treat Seborrheic Dermatitis in Individuals Aged ≥9 Years

  • April 19, 2023
Arcutis Reports the NDA Submission of Roflumilast to the US FDA for the Treatment of Seborrheic Dermatitis

Arcutis Reports the NDA Submission of Roflumilast to the US FDA for the Treatment of Seborrheic Dermatitis

  • February 22, 2023
Arcutis Reports P-II Study Results of Roflumilast for the Treatment of Chronic Plaque Psoriasis

Arcutis Reports P-II Study Results of Roflumilast for the Treatment of Chronic Plaque Psoriasis

  • January 16, 2023
Arcutis Reports P-III Trial (INTEGUMENT-2) Results of Roflumilast for the Treatment of Atopic Dermatitis in Adults and Children Aged ≥6 Years

Arcutis Reports P-III Trial (INTEGUMENT-2) Results of Roflumilast for the Treatment of Atopic Dermatitis in Adults and Children Ag...

  • December 13, 2022
Image

Incisive News in 3 Shots.

Contact Us

Our Information

Follow Us

Copyright © 2023 PharmaShots - All Rights Reserved.